David Pompliano

David Pompliano is a drug discovery scientist, entrepreneur and executive with 30 years of experience in the biopharmaceutical industry.

Working with venture capitalists and academicians, he creates scientifically precocious, game-changing new commercial enterprises based on groundbreaking discoveries in academic science. He co-founded and served as CSO of, Revolution Medicines (RVMD, a Third Rock company) and Lodo Therapeutics (an Accelerator company acquired by Zymergen, ZY), co-founded and is CEO of Daros, was co-founder and CEO of BioLeap, and raised over $70m in Series A financing. He also serves on the Boards of Directors and Scientific Advisory Boards of several biotechnology companies, government agencies, and philanthropies.

Earlier, as a senior pharmaceutical executive at GlaxoSmithKline and Merck, he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and five registered anti-infective (Recarbrio, Altabax) and oncology (Tykerb, Votrient, Promacta) drugs. As Principal and Owner at Sanderling Consulting LLC, he assists investors, companies and philanthropies in setting drug discovery strategies, executing the operations of preclinical discovery and development and evaluating pharmaceutical assets. Dr. Pompliano earned the BS and Ph.D. degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles’ laboratory at Harvard University. He has published more than 50 peer-reviewed papers in the areas of infectious diseases and cancer drug discovery and mechanistic enzymology and has presented over 50 invited lectures internationally.